Pancreatic Cancer

Volume 177 of the series Recent Results in Cancer Research pp 137-150

Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors

  • Karl-Hermann SchlingensiepenAffiliated withAntisense Pharma GmbH
  • , Birgit Fischer-BlassAffiliated withAntisense Pharma GmbH
  • , Susanne SchmausAffiliated withAntisense Pharma GmbH
  • , Sylvia LudwigAffiliated withAntisense Pharma GmbH

* Final gross prices may vary according to local VAT.

Get Access


Overexpression of the cytokine transforming growth factor-beta 2 (TGF-beta2) is a hallmark of various malignant tumors including pancreatic carcinoma, malignant glioma, metastasizing melanoma, and metastatic colorectal carcinoma. This is due to the pivotal role of TGF-beta2 as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. The antisense technology is an innovative technique offering a targeted approach for the treatment of different highly aggressive tumors and other diseases. Antisense oligonucleotides are being developed to inhibit the production of disease-causing proteins at the molecular level. The immunotherapeutic approach with the phosphorothioate oligodeoxynucleotide AP 12009 for the treatment of malignant tumors is based on the specific inhibition of TGF-beta2.